{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:04:34Z","timestamp":1785492274558,"version":"3.56.0"},"reference-count":157,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The liver and kidneys are two of the most vital organs, each with distinct but overlapping functions essential for maintaining homeostasis. The complex interplay between these organs, commonly referred to as liver-kidney crosstalk, plays a crucial role in the pathophysiology of several acute and chronic conditions in childhood. Despite its importance, the precise biological mechanisms driving this interaction remain incompletely understood. This crosstalk is particularly significant in various pediatric diseases (e.g., Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Hepatorenal Syndrome (HRS), genetic and metabolic disorders, etc.) where shared pathophysiological factors\u2014including systemic inflammation, metabolic disturbances, oxidative stress, and vascular dysfunction\u2014simultaneously affect both organs. Clinically, this interaction presents unique challenges in diagnosing, managing, and treating liver-kidney diseases in affected children. Understanding the pathogenic mechanisms underlying liver-kidney crosstalk is essential for improving patient care and outcomes through an integrated, multidisciplinary approach and personalized treatment strategies. This review aims to explore liver-kidney crosstalk in key pediatric diseases, offering a comprehensive overview of current knowledge, clinical challenges, and potential therapeutic interventions in this complex field.<\/jats:p>","DOI":"10.3390\/jcm14113911","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T10:21:49Z","timestamp":1748859709000},"page":"3911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges"],"prefix":"10.3390","volume":"14","author":[{"given":"Dario","family":"Piatto","sequence":"first","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"De Biasio","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giustino","family":"Cesaro","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Forcina","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Frattolillo","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9058-4933","authenticated-orcid":false,"given":"Antonio","family":"Colucci","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lamberti","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-0170","authenticated-orcid":false,"given":"Pierluigi","family":"Marzuillo","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Miraglia del Giudice","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-3757","authenticated-orcid":false,"given":"Anna","family":"Di Sessa","sequence":"additional","affiliation":[{"name":"Department of Woman, Child, and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cld.2022.01.008","article-title":"The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease","volume":"26","author":"Truong","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: An emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/ndt\/gfaa297","article-title":"Renohepatic crosstalk: A review of the effects of acute kidney injury on the liver","volume":"37","author":"Bonavia","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s11255-019-02288-x","article-title":"Kidney\u2013liver pathophysiological crosstalk: Its characteristics and importance","volume":"51","author":"Capalbo","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-015-0457-x","article-title":"The Kidney in Pediatric Liver Disease","volume":"17","author":"Matloff","year":"2015","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00467-017-3715-3","article-title":"Liver involvement in kidney disease and vice versa","volume":"33","author":"Mekahli","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4254\/wjh.v15.i6.741","article-title":"Recent advances in pathophysiology, diagnosis and management of hepatorenal syndrome: A review","volume":"15","author":"Kiani","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00467-020-04762-6","article-title":"Hepatorenal syndrome in children: A review","volume":"36","author":"Liu","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1478-3231.2011.02586.x","article-title":"New insights into the management of hepato-renal syndrome","volume":"31","author":"Hasper","year":"2011","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12098-023-04694-7","article-title":"Systemic Complications Secondary to Chronic Liver Disease","volume":"91","author":"Mannion","year":"2024","journal-title":"Indian J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41581-019-0218-4","article-title":"Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis","volume":"16","author":"Velez","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_13","first-page":"352","article-title":"Updates on Hepato-Renal Syndrome","volume":"4","author":"Fukazawa","year":"2013","journal-title":"J. Anesth. Clin. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cgh.2023.04.034","article-title":"Pathophysiology of Hepatorenal Syndrome\u2014Acute Kidney Injury","volume":"21","author":"Adebayo","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/liv.14037","article-title":"Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival","volume":"39","author":"Huelin","year":"2019","journal-title":"Liver Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MPG.0000000000003104","article-title":"Clinical Predictors of Morbidity and Mortality in Hospitalized Pediatric Patients with Ascites","volume":"73","author":"Ingviya","year":"2021","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.clinre.2022.101868","article-title":"Hepatic and non-hepatic hydrothorax in pediatric ascites","volume":"46","author":"Wasuwanich","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MPG.0000000000002643","article-title":"Long-term Outcomes and Health Perceptions in Pediatric-onset Portal Hypertension Complicated by Varices","volume":"70","author":"Luoto","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/liv.13693","article-title":"Profile, risk factors and outcome of acute kidney injury in paediatric acute-on-chronic liver failure","volume":"38","author":"Lal","year":"2018","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: An international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3350\/cmh.2021.0067","article-title":"From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?","volume":"27","author":"Kang","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.jhep.2024.03.007","article-title":"The MAFLD and MASLD conundrum: Is it reinvention of the wheel?","volume":"81","author":"Eslam","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jpn3.12219","article-title":"The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis\/cirrhosis among adolescents\/young adults","volume":"79","author":"Perumpail","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_28","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gutjnl-2023-331090","article-title":"Metabolic dysfunction-associated steatotic liver disease in children","volume":"74","author":"Goyal","year":"2025","journal-title":"Gut"},{"key":"ref_30","first-page":"533","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","article-title":"Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up","volume":"153","author":"Choe","year":"2024","journal-title":"Metabolism"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.3748\/wjg.v28.i39.5691","article-title":"Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations","volume":"28","author":"Theofilis","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3748\/wjg.v30.i15.2081","article-title":"Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective","volume":"30","author":"Nardolillo","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ndt\/gfr547","article-title":"Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function","volume":"27","author":"McCullough","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12072-023-10526-9","article-title":"MAFLD and chronic kidney disease: Two sides of the same coin?","volume":"17","author":"Pan","year":"2023","journal-title":"Hepatol Int."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pacifico, L., Bonci, E., Andreoli, G.M., Di Martino, M., Gallozzi, A., De Luca, E., and Chiesa, C. (2016). The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight\/Obesity. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081218"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sesti, G., Fiorentino, T.V., Arturi, F., Perticone, M., Sciacqua, A., and Perticone, F. (2014). Association between Noninvasive Fibrosis Markers and Chronic Kidney Disease among Adults with Nonalcoholic Fatty Liver Disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088569"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagstr\u00f6m, H., Yoon, S.K., and Charatcharoenwitthaya, P. (2014). Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001680"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic Fatty Liver Disease Is Independently Associated with an Increased Incidence of Chronic Kidney Disease in Patients with Type 1 Diabetes","volume":"37","author":"Targher","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/ndt\/gfs037","article-title":"Glomerular hyperfiltration: A marker of early renal damage in pre-diabetes and pre-hypertension","volume":"27","author":"Palatini","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_42","first-page":"605","article-title":"Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity","volume":"49","author":"Zarrilli","year":"2024","journal-title":"Int. J. Obes."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jpn3.12272","article-title":"Renal impairment is prevalent in pediatric NAFLD\/MASLD and associated with disease severity","volume":"79","author":"Mouzaki","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00431-024-05641-0","article-title":"Kidney function evaluation in children and adolescents with obesity: A not-negligible need","volume":"183","author":"Grella","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal Outcomes Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2020.03.038","article-title":"Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease","volume":"222","author":"Yodoshi","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic Inflammation\u2014A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474124.2021.1906649","article-title":"NAFLD and renal function in children: Is there a genetic link?","volume":"15","author":"Guarino","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00467-009-1134-9","article-title":"Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease","volume":"24","author":"Manco","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_52","first-page":"1517","article-title":"Metabolic risk factors in nondiabetic adolescents with glomerular hyperfiltration","volume":"32","author":"Lee","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.ki.5002160","article-title":"Glomerular hyperfiltration: A new marker of metabolic risk","volume":"71","author":"Tomaszewski","year":"2007","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41581-021-00423-5","article-title":"Lipoproteins and fatty acids in chronic kidney disease: Molecular and metabolic alterations","volume":"17","author":"Noels","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Mantovani, A., Targher, G., and Baffy, G. (2022). Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113320"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2021.09.029","article-title":"Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?","volume":"76","author":"Baffy","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CEG.S226130","article-title":"Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks","volume":"14","author":"Cheung","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"175219","DOI":"10.1016\/j.ejphar.2022.175219","article-title":"Crosstalk between the liver and kidney in diabetic nephropathy","volume":"931","author":"Yang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","article-title":"Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results from the PREVEND Study","volume":"108","author":"Post","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"154738","DOI":"10.1016\/j.metabol.2021.154738","article-title":"FGF21 and Chronic Kidney Disease","volume":"118","author":"Salgado","year":"2021","journal-title":"Metabolism"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1152\/ajpendo.00244.2022","article-title":"Fibroblast growth factor 21 as a potential master regulator in metabolic disorders","volume":"324","author":"Velingkar","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"19","author":"Pei","year":"2025","journal-title":"Gut Liver"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102495","DOI":"10.1016\/j.jceh.2024.102495","article-title":"Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis","volume":"15","author":"Souza","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e16106","DOI":"10.1111\/liv.16106","article-title":"PNPLA3 I148M Interacts with Environmental Triggers to Cause Human Disease","volume":"45","author":"Speliotes","year":"2025","journal-title":"Liver Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102389","DOI":"10.1016\/j.clinre.2024.102389","article-title":"Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population","volume":"48","author":"Rashu","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/hep.23832","article-title":"A Common Variant in the Patatin-Like Phospholipase 3 Gene (PNPLA3) Is Associated with Fatty Liver Disease in Obese Children and Adolescents","volume":"52","author":"Santoro","year":"2010","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e16010","DOI":"10.1111\/liv.16010","article-title":"PNPLA3 variation and kidney disease","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e33110","DOI":"10.1097\/MD.0000000000033110","article-title":"Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies","volume":"102","author":"Zhao","year":"2023","journal-title":"Medicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/apt.17477","article-title":"Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction","volume":"57","author":"Mantovani","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","article-title":"Association of MAFLD with end-stage kidney disease: A prospective study of 337,783 UK Biobank participants","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/liv.14419","article-title":"PNPLA3I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings","volume":"40","author":"Mantovani","year":"2020","journal-title":"Liver Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/liv.14251","article-title":"PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels","volume":"40","author":"Sun","year":"2020","journal-title":"Liver Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12944-023-01858-4","article-title":"Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus","volume":"22","author":"Liu","year":"2023","journal-title":"Lipids Health Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e12539","DOI":"10.1111\/ijpo.12539","article-title":"Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity","volume":"14","author":"Marzuillo","year":"2019","journal-title":"Pediatr. Obes."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.30625","article-title":"Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children with NAFLD","volume":"70","author":"Targher","year":"2019","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.jrn.2022.01.007","article-title":"PNPLA3 I148M Polymorphism Influences Renal Function in Children with Obesity and Prediabetes","volume":"32","author":"Russo","year":"2022","journal-title":"J. Ren. Nutr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00125-018-4805-x","article-title":"The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes","volume":"62","author":"Xia","year":"2019","journal-title":"Diabetologia."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e16164","DOI":"10.1111\/liv.16164","article-title":"Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease","volume":"45","author":"Seko","year":"2024","journal-title":"Liver Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.jhepr.2024.101092","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sato, S., Iino, C., Sasada, T., Soma, G., Furusawa, K., Yoshida, K., Sawada, K., Mikami, T., Nakaji, S., and Sakuraba, H. (2024). Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease. Genes, 15.","DOI":"10.3390\/genes15091172"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"326","DOI":"10.14218\/JCTH.2018.00022","article-title":"The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant","volume":"6","author":"Zhang","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17474124.2022.2032661","article-title":"Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease","volume":"16","author":"Xue","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Huang, G., Wallace, D.F., Powell, E.E., Rahman, T., Clark, P.J., and Subramaniam, V.N. (2023). Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102809"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e16124","DOI":"10.1111\/liv.16124","article-title":"Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"45","author":"Seko","year":"2024","journal-title":"Liver Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11892-021-01377-5","article-title":"Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications","volume":"21","author":"Martin","year":"2021","journal-title":"Curr. Diabetes Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.3748\/wjg.v26.i36.5474","article-title":"Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant","volume":"26","author":"Umano","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17\u03b2-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e23466","DOI":"10.1096\/fj.202302447R","article-title":"Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?","volume":"38","author":"Jakubek","year":"2024","journal-title":"FASEB J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Duni, A., Liakopoulos, V., Roumeliotis, S., Peschos, D., and Dounousi, E. (2019). Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease: Untangling Ariadne\u2019s Thread. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153711"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.2147\/JIR.S490418","article-title":"The NRF-2\/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"17","author":"Li","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Chambel, S.S., Santos-Gon\u00e7alves, A., and Duarte, T.L. (2015). The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/597134"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26882","DOI":"10.1074\/jbc.M114.567685","article-title":"Nuclear Heme Oxygenase-1 (HO-1) Modulates Subcellular Distribution and Activation of Nrf2, Impacting Metabolic and Anti-oxidant Defenses","volume":"289","author":"Biswas","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","article-title":"Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease\u2013associated thrombosis in mice","volume":"129","author":"Yang","year":"2017","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, T., Liu, W., Zhao, H., and Li, P. (2024). Research hotspots and future trends in lipid metabolism in chronic kidney disease: A bibliometric and visualization analysis from 2004 to 2023. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1401939"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chen, S.-C., Hung, C.-C., Kuo, M.-C., Lee, J.-J., Chiu, Y.-W., Chang, J.-M., Hwang, S.-J., and Chen, H.-C. (2013). Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055643"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/joim.12081","article-title":"High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease","volume":"274","author":"Baragetti","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Baragetti, A., Ossoli, A., Strazzella, A., Simonelli, S., Baragetti, I., Grigore, L., Pellegatta, F., Catapano, A.L., Norata, G.D., and Calabresi, L. (2020). Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072289"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e13695","DOI":"10.1111\/eci.13695","article-title":"Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis","volume":"52","author":"Guerra","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Dorotea, D., Koya, D., and Ha, H. (2020). Recent Insights Into SREBP as a Direct Mediator of Kidney Fibrosis via Lipid-Independent Pathways. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00265"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/10408363.2019.1711360","article-title":"Fructose and hepatic insulin resistance","volume":"57","author":"Softic","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Caliceti, C., Calabria, D., Roda, A., and Cicero, A.F.G. (2017). Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. Nutrients, 9.","DOI":"10.3390\/nu9040395"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review","volume":"8","author":"Salem","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3350\/cmh.2024.0782","article-title":"Bioactive metabolites: A clue to the link between MASLD and CKD?","volume":"31","author":"Chen","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Elshaer, A., Chascsa, D.M.H., and Lizaola-Mayo, B.C. (2024). Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Life, 14.","DOI":"10.3390\/life14070844"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Hammoud, S.H., AlZaim, I., Al-Dhaheri, Y., Eid, A.H., and El-Yazbi, A.F. (2021). Perirenal Adipose Tissue Inflammation: Novel Insights Linking Metabolic Dysfunction to Renal Diseases. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.707126"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/db20-1031","article-title":"Perirenal Fat Thickness Is Significantly Associated with the Risk for Development of Chronic Kidney Disease in Patients with Diabetes","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Reid, M.V., Fredickson, G., and Mashek, D.G. (2024). Mechanisms coupling lipid droplets to MASLD pathophysiology. Hepatology.","DOI":"10.1097\/HEP.0000000000001141"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2917474","DOI":"10.1155\/2020\/2917474","article-title":"PPAR\u03b3 and Its Agonists in Chronic Kidney Disease","volume":"2020","author":"Ma","year":"2020","journal-title":"Int. J. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"101777","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104617","DOI":"10.1016\/j.phrs.2019.104617","article-title":"The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease","volume":"152","author":"Raj","year":"2020","journal-title":"Pharmacol Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: The role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Cubero","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/mtod.2024.07","article-title":"Association of NAFLD\/NASH, and MAFLD\/MASLD with chronic kidney disease: An updated narrative review","volume":"4","author":"Lonardo","year":"2024","journal-title":"Metab. Target Organ Damage"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Cao, C., Zhu, H., Yao, Y., and Zeng, R. (2022). Gut Dysbiosis and Kidney Diseases. Front. Med., 9.","DOI":"10.3389\/fmed.2022.829349"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/advances\/nmab010","article-title":"Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis","volume":"12","author":"Zeng","year":"2021","journal-title":"Adv. Nutr. Int. Rev. J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7150\/ijms.51484","article-title":"Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: A systematic review and meta-analysis","volume":"18","author":"Jia","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Marzocco, S., Fazeli, G., Di Micco, L., Autore, G., Adesso, S., Dal Piaz, F., Heidland, A., and Di Iorio, B. (2018). Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study). J. Clin. Med., 7.","DOI":"10.3390\/jcm7100315"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hepr.14097","article-title":"Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period","volume":"55","author":"Mori","year":"2025","journal-title":"Hepatol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Gurun, M., Brennan, P., Handjiev, S., Khatib, A., Leith, D., Dillon, J.F., and Byrne, C.J. (2024). Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0299507"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dalbeni, A., Garbin, M., Zoncap\u00e8, M., Romeo, S., Cattazzo, F., Mantovani, A., Cespiati, A., Fracanzani, A.L., Tsochatzis, E., and Sacerdoti, D. (2023). Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115837"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.jhep.2023.10.021","article-title":"MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage","volume":"80","author":"Guarino","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/liv.16075","article-title":"Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies","volume":"44","author":"Pennisi","year":"2024","journal-title":"Liver Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e16159","DOI":"10.1111\/liv.16159","article-title":"Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study","volume":"45","author":"Bilson","year":"2024","journal-title":"Liver Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/2013.jamainternmed.85","article-title":"Body Mass Index in 1.2 Million Adolescents and Risk for End-Stage Renal Disease","volume":"172","author":"Vivante","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13052-024-01767-x","article-title":"Cardiometabolic risk in children and adolescents with obesity: A position paper of the Italian Society for Pediatric Endocrinology and Diabetology","volume":"50","author":"Valerio","year":"2024","journal-title":"Ital. J. Pediatr."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00431-024-05848-1","article-title":"Pediatric MASLD: Current understanding and practical approach","volume":"184","author":"Stroes","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Forcina, G., Luciano, M., Frattolillo, V., Mori, S., Monaco, N., Guarino, S., Marzuillo, P., Miraglia del Giudice, E., and Di Sessa, A. (2024). Kidney Damage in Pediatric Obesity: Insights from an Emerging Perspective. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237025"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00467-024-06623-y","article-title":"Kidney consequences of obesity","volume":"40","author":"Nehus","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.jhep.2024.01.004","article-title":"Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD\u2014Identifying the optimal pediatric label","volume":"80","author":"Wang","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Razavi, H., Sherman, M., Allen, A.M., Anstee, Q.M., Cusi, K., Friedman, S.L., Lawitz, E., Lazarus, J.V., and Schuppan, D. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors\u2019 Perspective. Aliment. Pharmacol. Ther.","DOI":"10.1111\/apt.70020"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jpn3.12399","article-title":"FISPGHAN statement on the global public health impact of metabolic dysfunction-associated steatotic liver disease","volume":"80","author":"Mitsinikos","year":"2025","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.obpill.2025.100164","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025","volume":"14","author":"Panganiban","year":"2025","journal-title":"Obes Pillars."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Oma\u00f1a-Guzm\u00e1n, I., Rosas-Diaz, M., Mart\u00ednez-L\u00f3pez, Y.E., Perez-Navarro, L.M., Diaz-Badillo, A., Alanis, A., Bustamante, A., Castillo-Ruiz, O., del Toro-Cisneros, N., and Esquivel-Hernandez, D.A. (2024). Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: A systematic review with meta-analysis and bibliometric analysis. BMC Med., 22.","DOI":"10.1186\/s12916-024-03744-x"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Smith, M.R., Yu, E.L., Malki, G.J., Newton, K.P., Goyal, N.P., Heskett, K.M., and Schwimmer, J.B. (2024). Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0314542"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.soard.2024.08.040","article-title":"Outcomes of adolescent bariatric surgery: Liver disease","volume":"21","author":"Brichta","year":"2025","journal-title":"Surg Obes Relat Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1056\/NEJMoa1603825","article-title":"Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism","volume":"376","author":"Stott","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12944-025-02474-0","article-title":"Hypothyroidism\/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: Advances in mechanism and treatment","volume":"24","author":"Pu","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for Children 6 to <12 Years of Age with Obesity\u2014A Randomized Trial","volume":"392","author":"Fox","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jpn3.12402","article-title":"Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease","volume":"80","author":"Hartmann","year":"2025","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/apt.70012","article-title":"The Lipidomic Profile Discriminates Between MASLD and MetALD","volume":"61","author":"Schneider","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Bourganou, M.V., Chondrogianni, M.E., Kyrou, I., Flessa, C.-M., Chatzigeorgiou, A., Oikonomou, E., Lambadiari, V., Randeva, H.S., and Kassi, E. (2025). Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202501.0541.v1"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:15Z","timestamp":1760031975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":157,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113911"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113911","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}